1.33
-0.09(-6.34%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.42 |
| Day High | 1.42 |
| Day Low | 1.3 |
| 52-Week High | 6.78 |
| 52-Week Low | 0.87 |
| Volume | 400,344 |
| Average Volume | 918,869 |
| Market Cap | 132.99M |
| PE | -1.06 |
| EPS | -1.26 |
| Moving Average 50 Days | 1.16 |
| Moving Average 200 Days | 2.83 |
| Change | -0.09 |
If you invested $1000 in Alector, Inc. (ALEC) since IPO date, it would be worth $73.56 as of June 01, 2025 at a share price of $1.33. Whereas If you bought $1000 worth of Alector, Inc. (ALEC) shares 5 years ago, it would be worth $40.17 as of June 01, 2025 at a share price of $1.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire Inc.
May 08, 2025 8:05 PM GMT
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer’s disease Continuing to pursue Alector Brain Carrier prog
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
GlobeNewswire Inc.
Apr 17, 2025 12:00 PM GMT
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Na
Alector Provides Executive Leadership Update
GlobeNewswire Inc.
Mar 28, 2025 8:05 PM GMT
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clin